Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

rly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Prescribing information and patient product information for JANUVIA and JANUMET are attached.

JANUVIA(TM) and JANUMET(TM) are trademarks of Merck & Co., Inc. -0-

JANUVIA(TM)(sitagliptin) Tablets                     9762701


    HIGHLIGHTS OF PRESCRIBING INFORMATION


    These highlights do not include all the information needed to use

JANUVIA safely and effectively. See full prescribing information for

JANUVIA.


    JANUVIA(TM) (sitagliptin) Tablets


    Initial U.S. Approval: 2006


    INDICATIONS AND USAGE


    JANUVIA is indicated as an adjunct to diet and exercise to improve

glycemic control in patients with type 2 diabetes mellitus (type 2

diabetes). JANUVIA is indicated for:


    --  Monotherapy (1.1)


    --  Combination therapy with metformin or a peroxisome

        proliferator-activated receptor gamma (PPAR-gamma) agonist

        (e.g., thiazolidinediones) when the single agent does not

        provide adequate glycemic control. (1.2)


    Important Limitations of Use: JANUVIA should not be used in

patients with type 1 diabetes mellitus (type 1 diabetes) or for the

treatment of diabetic ketoacidosis. (1.3)


    DOSAGE AND ADMINISTRATION


    The recommended dose of JANUVIA is 100 mg once daily as

monotherapy or as combination therapy with metformin or a PPAR-gamma

agonist (e.g., thiazolidinediones). (2.1)


    JANUVIA can be taken with or without food. (2.1)



  Dosage Adjustment in Patients With Moderate, Severe and End Stage

                      Renal Disease (ESRD) (2.2)

----------------------------------------------------------------------

           50 mg once daily                   25 mg once daily

--------------------------------------------------------------------
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... 20, 2014  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, announced today that it ... support a strong launch of Edwards Lifesciences Foundation,s new ... improve the global communities where its employees live and ... giving will exceed $8 million, including more than $7 ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... TARRYTOWN, N.Y., April 18, 2012 Bayer HealthCare today ... has cleared its CONTOUR® Next EZ, a new blood ... States.  CONTOUR Next EZ includes an easy-to-use meter and ... new BGM system is being introduced on a market-by-market ...
... launches their Latching Micro-D™ connectors with a new ... quick cable connections to rack and panel equipment.  ... weight, the new latching Micro-D™ connectors, at .050" ... including pull tests that exceeds 100 pound pull ...
Cached Medicine Technology:U.S. FDA Clears Bayer HealthCare's CONTOUR® Next EZ Blood Glucose Monitoring System 2U.S. FDA Clears Bayer HealthCare's CONTOUR® Next EZ Blood Glucose Monitoring System 3Omnetics Launches Panel Mounted Latching Micro-D™ Connectors 2
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are popular ... its new collection of power suppliers. Additionally, it has ... suppliers. All the new models come with big discounts, ... Dec. 20, 2014. , SWAccessControl.com has thousands of happy ... for a long time. It is very wise to ...
(Date:11/23/2014)... Church, VA (PRWEB) November 23, 2014 ... TV Have in Common, **FDAnews On-Demand Webinar**, Dec. 11, ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional activities ... , Now they're looking at websites, Twitter, ... Mark the calendar for Thursday, Dec. 11, for On-Demand ...
(Date:11/22/2014)... SC (PRWEB) November 23, 2014 Every ... to their communities. AlignLife experience rapid growth in the ... a very unique opportunity. AlignLife of Simpsonville ... AlignLife offices for their first annual Toy Drive. These ... charity they would support with this year's toy drive. ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... “Due to my knee replacement surgery, I had to ... using the ice grip attachment, I noticed how dangerous the ... be a safer way to prevent possible injuries, so I ... BLOCK offers added safety and stability in slick and icy ... and damage associated with traditional spiked ice grips. As a ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... , , MISSION VIEJO, Calif., Sept. ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative ... of Directors has declared a quarterly cash dividend of $0.045 per ... 2009 to shareholders of record as of September 30, 2009. Ensign ...
... BOTHELL, Wash., Sept. 18 SCOLR Pharma, Inc. ... September 15, 2009, the NYSE Amex LLC (the "Exchange") accepted ... disclosed listing deficiency as set forth in Section 1003(a)(iii) of ... Company,s failure to maintain stockholder,s equity of at least $6,000,000 ...
... , , LAWRENCE, Mass., Sept. ... leading manufacturer of innovative dialysis products, today announced that home dialysis ... Road Trip" with the NxStage(R) System One(TM). As a portable ... opportunity to fit hemodialysis therapy into his own lifestyle and schedule. ...
... , , , , ... hip abnormalities, combined with advances in diagnostic imaging techniques and minimally ... chronic, misdiagnosed hip pain. , , Increasingly, ... of degenerative hip disease, get patients back to their chosen activities ...
... , Statement of Andy Stern, President of ... Andy Stern, President of the Service Employees International Union, ... extremists to silence working families by attacking progressive individuals and community ... of profound change for this country -- from kitchen tables to ...
... , , HAYWARD, Calif., Sept. ... global leader in the medical aesthetics market, today announced that it ... on Tuesday, September 29, 2009 at the Grand Hyatt New York ... for 10:30 a.m. Eastern Time on September 29, 2009. Stephen ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 2Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 4Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 5Health News:Working Women and Men Will Not Be Silenced by Right Wing Attack Dogs; SEIU Members and Other Working Americans Will Continue to Speak Out For the America We Believe In 2Health News:Solta Medical to Present at the Maxim Group Growth Conference 2
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: